Pharma & Biotech VC & Investment News
Biotechnology
Danish life sciences investor Novo Holdings is continuing the spread of its cash pile, this time as co-leader of a $181.4 million Series D financing in Alentis Therapeutics. 12 November 2024
Today's issue
Refine Search
Biotechnology
San Diego-based Cidara Therapeutics, a biotech using its proprietary Cloudbreak platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, has entered into a securities purchase agreement with certain investors to raise up to around $105 million. 21 November 2024
Biotechnology
Aizen Therapeutics, an AI-driven biotech headquartered in San Diego, has officially launched from stealth mode, introducing its drug discovery platform, DaX. 21 November 2024
Biotechnology
San Diego-based Valora Therapeutics, a biotech that boasts of having a novel approach to immunotherapy, has announced the successful closing of a $30 million seed funding round. 21 November 2024
article
The UK government has reappointed BioIndustry Association (BIA) chairman Daniel Mahony as its Life Sciences Investment Envoy. 21 November 2024
Pharmaceutical
Shanghai-based Leading Tac Pharmaceutical has announced the successful completion of a series A financing round, raising over 100 million yuan ($14 million). 21 November 2024
Biotechnology
A pair of industry veterans have teamed up to create Jupiter Bioventures, a San Francisco-based biotech venture foundry promised to build bold, science-driven therapeutics companies. 20 November 2024
Biotechnology
Aclaris Therapeutics has announced an exclusive licensing agreement with Biosion for broad rights to two new antibodies. 19 November 2024
Biotechnology
Californian oncology-focused biotech Avenzo Therapeutics has announced a pair of important updates. 19 November 2024
Pharmaceutical
In yet another sign of the mounting interest in radiopharmaceuticals, Tongrui Biopharma, a Chinese innovator in this area, has announced the completion of a $100 million series A+ financing round. 18 November 2024
Biotechnology
Shanghai-based biopharma Zai Lab has announced the pricing of its underwritten public offering at $25.50 per share, aiming to raise around $200 million. 15 November 2024
Pharmaceutical
New York-based Metsera, a biopharma developing medicines for obesity and metabolic diseases, has closed a $215 million Series B financing to further advance its portfolio of clinical-stage, nutrient-stimulated hormone (NuSH) analog peptides. 14 November 2024
Pharmaceutical
Life science investor Syncona has announced the launch of its newest portfolio company, Slingshot Therapeutics, through the Syncona Accelerator initiative. 14 November 2024
Biotechnology
Danish life sciences investor Novo Holdings is continuing the spread of its cash pile, this time as co-leader of a $181.4 million Series D financing in Alentis Therapeutics. 12 November 2024
Biotechnology
Trace Neuroscience, a newly launched biopharma based in San Francisco, aims to advance treatments for neurodegenerative diseases, starting with amyotrophic lateral sclerosis (ALS). 12 November 2024
Biotechnology
Geron Corporation, a biopharma company focused on telomerase inhibition therapies, has announced a $375 million financing agreement aimed at supporting the commercial rollout of Rytelo (imetelstat). 11 November 2024
Biotechnology
An Expert View from Cumulus Oncology about its innovative business model, which is all about improving the efficiency of drug R&D. 11 November 2024
Biotechnology
US biotech venture fund Aditum Bio and China’s Leads Biolabs today announced the formation of Oblenio Bio, marking the thirteenth company launched by Aditum. 7 November 2024
Pharmaceutical
PrognomiQ has announced a series D financing round of $34 million, led by Seer, bringing the firm’s total funding to over $135 million since its founding in September 2020. 6 November 2024
Pharmaceutical
Syndax Pharmaceuticals has entered into a $350 million royalty funding agreement with Royalty Pharma. 6 November 2024
Biotechnology
A new Seattle-based biotech company has the best endorsement imaginable as it emerges from stealth. Archon Biosciences’ platform, leveraging AI-driven advances in computational protein design, were recognized earlier this month by the awarding of the 2024 Nobel Prize in Chemistry, for its ability to create novel proteins with desired functions. 31 October 2024
Biotechnology
US biotech Mammoth Biosciences has secured $195 million in financing, joining the select ranks of “unicorn” start-ups with a valuation of more than $1 billion. 10 September 2021
Biotechnology
A Scotland-based company that claims to be pioneering the future of modern medicine through microbiome-modulating therapeutics now has $21.5 million more to deliver on the promise. 7 September 2021
Biotechnology
All signs point to an M&A boom in late 2021 and throughout 2022. In this episode, Lance Minor, principal and national co-leader of the life sciences practice at BDO, provides valuable insight into current and emerging trends in the biotech investing landscape. 1 September 2021
Biotechnology
Laronde, a US company developing what it calls an Endless RNA (eRNA) platform, has raised $440 million in a Series B financing. 31 August 2021
Biotechnology
US biotech Humacyte has announced the successful completion of its business combination with Alpha Healthcare Acquisition Corp (AHAC), a special purpose acquisition company (SPAC) sponsored by Constellation Alpha Holdings. 27 August 2021
Biotechnology
A $60 million Series A financing has shown that Boston-based biotech Atavistik Bio means business in metabolic disease and cancer. 25 August 2021
Biotechnology
Abogen Biosciences has closed an impressive Series C financing, raising more than $700 million. 20 August 2021
Pharmaceutical
Boston, USA-based start-up Jnana Therapeutics today announced the closing of a $50 million Series B financing, led by RA Capital Management, and included all existing investors, including Polaris Partners, Versant Ventures, Avalon Ventures, AbbVie Ventures and Pfizer Ventures. 18 August 2021
Pharmaceutical
For many years, industry commentators have observed that there could be huge untapped therapeutic potential for psychedelics, should the correct development pathways be found. 18 August 2021
Biotechnology
Yet another public listing via special purpose acquisition company (SPAC) demonstrates the growing popularity of the approach, as an alternative to the traditional initial public offering. 11 August 2021
Pharmaceutical
Japan’s Otsuka Pharmaceuticals has been handed a grant for up to $17.8 million from the Bill & Melinda Gates Foundation to support the clinical trial of a treatment-shortening regimen in drug-sensitive tuberculosis (TB). 11 August 2021
Pharmaceutical
A self-styled pioneer that promises to develop and deliver innovative medicines to patients at radically lower prices, is to raise up to $1.8 billion via a combination with special purpose acquisition company (SPAC) CM Life Sciences III, as it looks to accelerate its growth. 9 August 2021
Biotechnology
For the second time since its initiation in 2014, a research partnership between AbbVie and Calico Life Sciences has been extended, bringing the total investment to over $3 billion. 28 July 2021
Pharmaceutical
US companies Arena Pharmaceuticals and Aristea Therapeutics have entered into a strategic collaboration to advance the clinical development of RIST4721, an oral CXCR2 antagonist being developed by Aristea for the treatment of palmoplantar pustulosis (PPP) and other neutrophil-mediated diseases. 28 July 2021
Biotechnology
Swiss biotech AC Immune today announced that it is acquiring Austrian vaccine specialist Affiris’ portfolio of therapeutics targeting alpha-synuclein (a-syn), notably Affiris PD01, a clinically-validated active vaccine candidate for the treatment of Parkinson’s disease, as well as cash. 27 July 2021
Biotechnology
The Australian government in the state of Victoria has announced that a novel coronavirus vaccine candidate will enter clinical testing in October, with preliminary results expected in the first half of 2022. 23 July 2021
Biotechnology
USA-based microbiome company Vedanta Biosciences today announced the closing of a $68 million Series D financing. 21 July 2021
Biotechnology
US biotherapeutics company Gelesis is to go public via a merger with Capstar Special Purpose Acquisition, a special purpose acquisition company. 20 July 2021
Biotechnology
US biotech Amylyx Pharmaceuticals has announced the closing of an oversubscribed $135 million Series C financing. 20 July 2021
Biotechnology
California-based Frontier Medicines Corporation, a precision medicine company seeking to unlock the proteome to advance breakthroughs against otherwise undruggable disease-causing targets, has announced the closing of an $88.5 million Series B financing round. 19 July 2021
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze